Sartorius has completed the acquisition of selected life science businesses of Danaher Corp. for $825 million, expanding its market position in bioanalytics as well as key areas of the manufacture of biopharmaceuticals.

The acquired businesses, which become two divisions of the Sartorius Group, generated revenue of approximately $170 million in 2019 and cover various lab and bioprocessing technologies.
 
The FortéBio business for label-free biomolecular characterization includes protein analysis instruments, biosensors and reagents that are used in drug discovery and will be integrated into the Bioanalytics unit within the Sartorius Lab Products & Services Division. FortéBio employs approximately 200 people worldwide, has production sites in Fremont, CA, and Shanghai, China, and accounts for close to half of the revenue generated by the acquired businesses.

With the chromatography systems and resins business also acquired, Sartorius is expanding the portfolio of its Bioprocess Solutions Division in the downstream processing area. This business addresses an essential step in the purification of biopharmaceuticals and encompasses both reusable and single-use equipment, columns and resins. A further asset to be allocated to the Bioprocess Solutions Division is the SoloHill business covering microcarrier technology and particle validation standards used in cell cultures and other bioprocesses. Together, these various business entities employ approximately 100 people at sites in Portsmouth, UK; Cergy, France; Ann Arbor, MI; and Hopkinton, MA.